EUVIMEDEUVIMED entdecken
Kommentar

HRS-4642: The next piece of the puzzle to keep KRAS in check

Alejandra A Flores-Gómez, Matthias Drosten

Cancer Cell · 2024-07 · 42 (7) · 1157-1159

DOI: 10.1016/j.ccell.2024.06.005 ↗

Kurz gefasst

Kommentar in der Zeitschrift Cancer Cell, 2024-07. Verfasst von Alejandra A Flores-Gómez und 1 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Mechanisms of Cancer Program, Centro de Investigación del Cáncer (CIC), Salamanca, Spain; Instituto de Biología Molecular y Celular del Cán…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras). Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 10 Literaturangaben. Gefördert von: Gobierno de España Ministerio de Ciencia, Innovación y Universidades, Fundacion Cientifica de la Asociacion Espanola Contra el Cancer, Ministerio de Ciencia e Innovación.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

KRASG12D is the most frequent KRAS mutation in human cancer. In this issue, Zhou et al. describe a novel KRASG12D inhibitor, HRS-4642, that shows potent and selective anti-tumor activity across various models and synergizes with proteasome inhibitors. Responses have also been observed in patients during an ongoing phase 1 trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)HumansNeoplasmsMutationAntineoplastic AgentsAnimalsProteasome Inhibitors

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, humanAntineoplastic AgentsProteasome Inhibitors

Autor:innen und Institutionen

  • Molecular Mechanisms of Cancer Program, Centro de Investigación del Cáncer (CIC), Salamanca, Spain; Instituto de Biología Molecular y Celular del Cáncer (IBMCC), CSIC-USAL, Salamanca, Spain.
  • Molecular Mechanisms of Cancer Program, Centro de Investigación del Cáncer (CIC), Salamanca, Spain; Instituto de Biología Molecular y Celular del Cáncer (IBMCC), CSIC-USAL, Salamanca, Spain. Electronic address: mdrosten…

Förderung

  • Gobierno de España Ministerio de Ciencia, Innovación y Universidades
  • Fundacion Cientifica de la Asociacion Espanola Contra el Cancer
  • Ministerio de Ciencia e Innovación
  • Consejo Nacional de Humanidades, Ciencias y Tecnologías

Zitieren

APA

Flores-Gómez, A. A., & Drosten, M. (2024). HRS-4642: The next piece of the puzzle to keep KRAS in check. Cancer Cell, 42(7), 1157-1159. https://doi.org/10.1016/j.ccell.2024.06.005

Vancouver

Flores-Gómez AA, Drosten M. HRS-4642: The next piece of the puzzle to keep KRAS in check. Cancer Cell. 2024;42(7):1157-1159. doi:10.1016/j.ccell.2024.06.005

BibTeX
@article{FloresGmez2024,
  author = {Flores-Gómez, Alejandra A and Drosten, Matthias},
  title = {HRS-4642: The next piece of the puzzle to keep KRAS in check},
  journal = {Cancer Cell},
  year = {2024},
  volume = {42},
  number = {7},
  pages = {1157--1159},
  doi = {10.1016/j.ccell.2024.06.005}
}
Kostenlos starten →